Cargando…

Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation

Background and aim The use of non-steroidal anti-inflammatory drugs in animals decreases the incidence of posterior capsular opacification (PCO) following cataract surgery. We evaluated the rate of PCO in patients with cataract surgery and foldable “in the bag” posterior chamber intraocular lens (PC...

Descripción completa

Detalles Bibliográficos
Autores principales: Evereklioglu, Cem, Arda, Hatice, Sener, Hidayet, Polat, Osman A, Gumus, Koray, Horozoglu, Fatih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163951/
https://www.ncbi.nlm.nih.gov/pubmed/37159777
http://dx.doi.org/10.7759/cureus.37223
_version_ 1785037988465475584
author Evereklioglu, Cem
Arda, Hatice
Sener, Hidayet
Polat, Osman A
Gumus, Koray
Horozoglu, Fatih
author_facet Evereklioglu, Cem
Arda, Hatice
Sener, Hidayet
Polat, Osman A
Gumus, Koray
Horozoglu, Fatih
author_sort Evereklioglu, Cem
collection PubMed
description Background and aim The use of non-steroidal anti-inflammatory drugs in animals decreases the incidence of posterior capsular opacification (PCO) following cataract surgery. We evaluated the rate of PCO in patients with cataract surgery and foldable “in the bag” posterior chamber intraocular lens (PC-IOL) implantation treated with combined dexamethasone 0.1% plus ketorolac tromethamine 0.5% versus dexamethasone 0.1% alone. Materials and methods A total of 114 eyes of 101 patients underwent uneventful corneal small-incision phacoemulsification with primary implantation of a foldable acrylic PC-IOL (AcrySof(®), Alcon, Fort Worth, USA). Postoperatively for four weeks, group 1 eyes were treated with dexamethasone 0.1% plus ketorolac tromethamine 0.5% ophthalmic solutions four times daily for each whereas group 2 eyes were treated with dexamethasone 0.1% alone. Other regiments were the same for each group. Patients were evaluated between one- and four-year following surgery. The frequency and timing of severe PCO following surgery that needed Nd:YAG laser posterior capsulotomy were recorded and evaluated. Results The mean (SEM) age of group 1 (n = 54) and group 2 (n = 60) at operation was similar (62.8 ± 2.2 vs. 60.6 ± 1.7 years, respectively). Eighty-eight patients had unilateral cataract and 13 cases had bilateral disease. Overall, the mean follow-up duration was 24.7 months postoperatively (range, 15-48). Clinically significant PCO that finally needed Nd:YAG laser application developed in two eyes (3.7%) in group 1 and in four eyes (6.6%) in group 2, and the difference was not statistically significant (p>0.05). The mean month at capsulotomy was 26.5 in group 1 and 24.3 months in group 2 eyes (p>0.05). Conclusions Topical instillation of ketorolac ophthalmic solution in the immediate period after phacoemulsification and PC-IOL implantation did not seem to influence the incidence of PCO formation two years after cataract surgery.
format Online
Article
Text
id pubmed-10163951
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101639512023-05-07 Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation Evereklioglu, Cem Arda, Hatice Sener, Hidayet Polat, Osman A Gumus, Koray Horozoglu, Fatih Cureus Ophthalmology Background and aim The use of non-steroidal anti-inflammatory drugs in animals decreases the incidence of posterior capsular opacification (PCO) following cataract surgery. We evaluated the rate of PCO in patients with cataract surgery and foldable “in the bag” posterior chamber intraocular lens (PC-IOL) implantation treated with combined dexamethasone 0.1% plus ketorolac tromethamine 0.5% versus dexamethasone 0.1% alone. Materials and methods A total of 114 eyes of 101 patients underwent uneventful corneal small-incision phacoemulsification with primary implantation of a foldable acrylic PC-IOL (AcrySof(®), Alcon, Fort Worth, USA). Postoperatively for four weeks, group 1 eyes were treated with dexamethasone 0.1% plus ketorolac tromethamine 0.5% ophthalmic solutions four times daily for each whereas group 2 eyes were treated with dexamethasone 0.1% alone. Other regiments were the same for each group. Patients were evaluated between one- and four-year following surgery. The frequency and timing of severe PCO following surgery that needed Nd:YAG laser posterior capsulotomy were recorded and evaluated. Results The mean (SEM) age of group 1 (n = 54) and group 2 (n = 60) at operation was similar (62.8 ± 2.2 vs. 60.6 ± 1.7 years, respectively). Eighty-eight patients had unilateral cataract and 13 cases had bilateral disease. Overall, the mean follow-up duration was 24.7 months postoperatively (range, 15-48). Clinically significant PCO that finally needed Nd:YAG laser application developed in two eyes (3.7%) in group 1 and in four eyes (6.6%) in group 2, and the difference was not statistically significant (p>0.05). The mean month at capsulotomy was 26.5 in group 1 and 24.3 months in group 2 eyes (p>0.05). Conclusions Topical instillation of ketorolac ophthalmic solution in the immediate period after phacoemulsification and PC-IOL implantation did not seem to influence the incidence of PCO formation two years after cataract surgery. Cureus 2023-04-06 /pmc/articles/PMC10163951/ /pubmed/37159777 http://dx.doi.org/10.7759/cureus.37223 Text en Copyright © 2023, Evereklioglu et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Ophthalmology
Evereklioglu, Cem
Arda, Hatice
Sener, Hidayet
Polat, Osman A
Gumus, Koray
Horozoglu, Fatih
Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation
title Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation
title_full Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation
title_fullStr Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation
title_full_unstemmed Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation
title_short Comparison of the Rate of Posterior Capsule Opacification Following Combined Treatment With Topical Dexamethasone 0.1% Plus Ketorolac 0.5% Eye Drops Versus Dexamethasone 0.1% Alone: A Two-Year, Randomized Clinical Investigation
title_sort comparison of the rate of posterior capsule opacification following combined treatment with topical dexamethasone 0.1% plus ketorolac 0.5% eye drops versus dexamethasone 0.1% alone: a two-year, randomized clinical investigation
topic Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163951/
https://www.ncbi.nlm.nih.gov/pubmed/37159777
http://dx.doi.org/10.7759/cureus.37223
work_keys_str_mv AT evereklioglucem comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation
AT ardahatice comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation
AT senerhidayet comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation
AT polatosmana comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation
AT gumuskoray comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation
AT horozoglufatih comparisonoftherateofposteriorcapsuleopacificationfollowingcombinedtreatmentwithtopicaldexamethasone01plusketorolac05eyedropsversusdexamethasone01aloneatwoyearrandomizedclinicalinvestigation